Published in Patient Prefer Adherence on February 02, 2015
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65
An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92
Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med (2013) 2.92
Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med (2012) 2.81
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med (2013) 2.75
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med (2014) 2.48
Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care (2009) 2.36
Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 2.21
Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75
Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm (2012) 1.71
Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med (2013) 1.62
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus (2014) 1.49
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest (2014) 1.47
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis (2014) 1.33
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med (2013) 1.31
Medication adherence patterns in chronic obstructive pulmonary disease. Chest (1991) 1.30
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med (2012) 1.30
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis (2014) 1.25
Patient-level medication regimen complexity across populations with chronic disease. Clin Ther (2013) 1.24
COPD in the general population: prevalence, incidence and survival. Respir Med (2011) 1.22
Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med (2013) 1.15
Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open (2012) 1.13
Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res (2013) 1.09
Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One (2012) 1.08
Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 1.07
Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther (2012) 1.06
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol (2012) 1.02
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther (2012) 1.02
Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis (2014) 1.01
Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin (2012) 0.98
Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest (2014) 0.97
Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration (2011) 0.96
Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin (2009) 0.96
Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin (2010) 0.96
Multiple dose regimens. Impact on compliance. Chest (1995) 0.95
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Investig (2013) 0.94
Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther (2007) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis (2014) 0.91
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med (2011) 0.89
Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence (2011) 0.89
Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet (2014) 0.86
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend. Am Health Drug Benefits (2014) 0.86
Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat (2013) 0.84
The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Rev Port Cardiol (2014) 0.84
Medication adherence behaviors of Medicare beneficiaries. Patient Prefer Adherence (2014) 0.83
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med (2004) 0.83
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med (2014) 0.83
Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin Drug Deliv (2014) 0.82
Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics (2004) 0.82
Medication adherence: process for implementation. Patient Prefer Adherence (2014) 0.81
The adherence and illness perception of patients diagnosed with asthma or chronic obstructive pulmonary disease treated with polytherapy using new generation Cyclohaler. Postepy Dermatol Alergol (2014) 0.81
Inhaled drug delivery in the hands of the patient. J Aerosol Med Pulm Drug Deliv (2014) 0.81
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis (2014) 0.79
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulm Pharmacol Ther (2014) 0.79
Relationship Between Medication Adherence and Health-Related Quality of Life in Subjects With COPD: A Systematic Review. Respir Care (2014) 0.79
Umeclidinium/Vilanterol: first global approval. Drugs (2014) 0.77